<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>SGC UNC Chapel Hill &#8211; openlabnotebooks.org</title>
	<atom:link href="https://thesgc.github.io/static-openlabnotebooks/category/laboratory/sgc-unc/feed/" rel="self" type="application/rss+xml" />
	<link>https://thesgc.github.io/static-openlabnotebooks/</link>
	<description>A growing team of groundbreaking scientists around the world are now sharing their lab notebooks online</description>
	<lastBuildDate>Tue, 16 Jul 2019 04:01:32 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=4.9.10</generator>

<image>
	<url>https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/01/cropped-lab-jar02-32x32.png</url>
	<title>SGC UNC Chapel Hill &#8211; openlabnotebooks.org</title>
	<link>https://thesgc.github.io/static-openlabnotebooks/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Gram-scale synthesis of furopyridines</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/gram-scale-synthesis-of-furopyridines/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/gram-scale-synthesis-of-furopyridines/#comments</comments>
		<pubDate>Thu, 27 Jun 2019 15:39:07 +0000</pubDate>
		<dc:creator><![CDATA[Sean O'Byrne]]></dc:creator>
				<category><![CDATA[Sean O'Byrne]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=3029</guid>
		<description><![CDATA[Access to large amounts of core building blocks is essential in drug discovery programs. It enables rapid synthesis of a series which can then give structure activity relationships (SAR) of the drugs and their target. SAR data allows medicinal chemists to determine the group(s) in a structure evoke a change in activity, whether positive or <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/gram-scale-synthesis-of-furopyridines/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">Access to large amounts of core building blocks is essential in drug discovery programs. It enables rapid synthesis of a series which can then give structure activity relationships (SAR) of the drugs and their target. SAR data allows medicinal chemists to determine the group(s) in a structure evoke a change in activity, whether positive or negative. A comprehensive SAR directs medical chemists towards the next target and greatly enhances the drug discover effort.</p>
<div style="width: 230px" class="wp-caption aligncenter"><img src="data:image/png;base64,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" width="220" height="90" alt="" class="" /><p class="wp-caption-text">Figure 1: Quinoline and furopyridine cores.</p></div>
<p style="text-align: justify;">When I joined this project there were two main pharmacophores that were being explored, quinolines and furopyridines (<strong>Figure 1</strong>). The quinoline core has been utilized for decades in drugs, one notable example being chloroquine, historically one of the most successful anti-malarial drugs to be marketed. The quinoline core is commercially available with various handles/substitution patterns for derivatization. The furopyridine core if much less common in clinical drugs. The most notable example of a furopyridine core in a drug is the HIV protease inhibitor L-754,394 (<strong>Figure 2</strong>).</p>
<div style="width: 234px" class="wp-caption aligncenter"><img src="data:image/png;base64,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" width="224" height="122" alt="" /><p class="wp-caption-text">Figure 2: L-754,394</p></div>
<p style="text-align: justify;">The furopyridine core is less common in clinical drugs due in part to the lack of synthetic routes to the core. The routes that are published suffer from poor to moderate yields and give restricted opportunities to derivatize the core. Indeed, when I joined this project, progress in the furopyridine series was severely limited due to the inaccessibility of the core with the required handles. When the project was first initiated, a bromofuropyridine <strong>1</strong> was commercially available. This was subjected to Suzuki coupling followed by bromination to give another synthetic handle (<strong>Scheme 1</strong>). This route was expensive, slow and problematic, often affording side-products that were poly-brominated and difficult to separate by column chromatography.</p>
<div style="width: 498px" class="wp-caption aligncenter"><img src="data:image/png;base64,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" width="488" height="71" alt="" /><p class="wp-caption-text">Scheme 1: Initial route to furopyridine derivatives.</p></div>
<p style="text-align: justify;">This route quickly became redundant when the starting material <strong>1 </strong>was no longer commercially available. In any case an alternative, more effective, route was needed to optimize access to the core with the required handles for analogue synthesis.</p>
<p style="text-align: justify;">An alternative route was derived from a synthesis published in 1986 by Hiroyuki Morita and Shunsaku Shiotani (<strong>Scheme 2</strong>). Although the route looks good on paper it has some severe drawbacks. Firstly, the saponification-decarboxylation of ester <strong>6</strong> is extremely unreliable. The ester is surprising stable to acidic and basic conditions. When increasingly harsh conditions are used it often leads to decomposition of the core over hydrolysis. 41% was the best yield achieved in over 30 attempts using various conditions. Most frustratingly, when effective saponification conditions (<sup>t</sup>BuOH/aq. LiOH at reflux) were found, the acid was isolated, and the decarboxylation could not be forced under acidic, basic or thermal conditions. This suggests the basic saponification conditions inhibited the decarboxylation and acidic hydrolysis is required to enable the decarboxylation.</p>
<p style="text-align: justify;">The second issue was the reactivity of the bromine and triflate of compound <strong>8</strong> to cross-coupling. Considerable effort was invested trying to find conditions for selectively coupling the triflate but in no case could complete selectivity be achieved.</p>
<div style="width: 484px" class="wp-caption aligncenter"><img src="data:image/png;base64,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" width="474" height="164" alt="" /><p class="wp-caption-text">Scheme 2: Unoptimized route to the furopyridine core.</p></div>
<p style="text-align: justify;">To overcome these issues and streamline the route I decided to start with a dichloro derivative of nicotinic acid. Chlorine is much less active to cross-coupling than bromine and hence should allow for the triflate to couple exclusively. To address the saponification-decarboxylation step I decided to synthesize a <em>tert</em>-butyl ester which can be easily removed under mild acidic conditions. The updated route is shown in <strong>Scheme 3</strong>.</p>
<div style="width: 550px" class="wp-caption aligncenter"><img src="data:image/png;base64,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" width="540" height="189" alt="" /><p class="wp-caption-text">Scheme 3: Optimized route to the furopyridine core.</p></div>
<p style="text-align: justify;">Gratifyingly the route straightforward and reliable. Out of the four steps only 2 required purification <em>via </em>column chromatography. It is effective on a large scale and several grams of the furopyridine core can be made. Started from 5 grams of the dichloronicotinic acid <strong>9</strong>, over 3 grams for furopyridine <strong>12</strong> was generated, amounting to a 70% yield over 3 steps.</p>
<p style="text-align: justify;">Furthering this when compound <strong>13 </strong>is subjected to palladium cross-coupling, the triflate shows much higher reactivity and exclusively couples first. This optimized route to the furopyridine core is now allowing us to generate a large set of compounds based on the furopyridine core. A large number have been sent for testing in an enzymatic assay for CaMKK2 with our collaborators and the results will be discussed in the future.</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/gram-scale-synthesis-of-furopyridines/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>CaMKK2 Inibitors: Quinoline Analogs</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/camkk2-inibitors-quinoline-analogs/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/camkk2-inibitors-quinoline-analogs/#respond</comments>
		<pubDate>Mon, 24 Jun 2019 04:42:52 +0000</pubDate>
		<dc:creator><![CDATA[Benjamin Eduful]]></dc:creator>
				<category><![CDATA[Ben Eduful]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2978</guid>
		<description><![CDATA[In my last post, I reported a new synthetic route to our quinoline series, Scheme 1. The goal was to overcome prior synthetic challenges and to allow for rapid synthesis of many different analogs over a short period of time. Scheme 1: New synthetic route for generating quinoline analogs I have as a result generated large <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/camkk2-inibitors-quinoline-analogs/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p>In my last post, I reported a new synthetic route to our quinoline series, <strong>Scheme 1</strong>. The goal was to overcome prior synthetic challenges and to allow for rapid synthesis of many different analogs over a short period of time.</p>
<p style="text-align: center;"><strong>Scheme 1: New synthetic route for generating quinoline analogs</strong></p>
<p><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/Quin-1-300x78.png" alt="" width="662" height="172" class=" wp-image-2981 aligncenter" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/Quin-1-300x78.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/Quin-1-768x201.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/Quin-1-1024x268.png 1024w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/Quin-1.png 1037w" sizes="(max-width: 662px) 100vw, 662px" /></p>
<p>I have as a result generated large numbers of quinoline analogs which have been sent for testing &#8211; CaMKK2 binding assay. Examples of some of the completed analogs are provided below, <strong>Figure 1</strong>.</p>
<p style="text-align: center;"><strong>Figure 1: Prepared quinoline analogs (CaMKK2 Inhibitors)</strong></p>
<p><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/Quin-2-1.png" alt="" width="89" height="121" class="wp-image-2989 aligncenter" /></p>
<p><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-3-300x298.png" alt="" width="374" height="372" class=" wp-image-2990 aligncenter" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-3-300x298.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-3-150x150.png 150w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-3.png 513w" sizes="(max-width: 374px) 100vw, 374px" /></p>
<p><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-4-300x244.png" alt="" width="372" height="302" class=" wp-image-2991 aligncenter" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-4-300x244.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-4.png 494w" sizes="(max-width: 372px) 100vw, 372px" /></p>
<p><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-5-300x238.png" alt="" width="397" height="315" class=" wp-image-2992 aligncenter" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-5-300x238.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-5.png 527w" sizes="(max-width: 397px) 100vw, 397px" /></p>
<p><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/quin-6.png" alt="" width="127" height="97" class="wp-image-2993 aligncenter" /></p>
<p>I am currently analyzing all of the biological data received so far and they will be reported in due course.</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/camkk2-inibitors-quinoline-analogs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Synthesis of promiscuous ALK2 inhibitors-continuation-2</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors-continuation-2/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors-continuation-2/#respond</comments>
		<pubDate>Thu, 13 Jun 2019 20:34:07 +0000</pubDate>
		<dc:creator><![CDATA[Alfredo Picado]]></dc:creator>
				<category><![CDATA[ACVR1/ALK2]]></category>
		<category><![CDATA[Alfredo Picado]]></category>
		<category><![CDATA[Diffuse intrinsic pontine glioma]]></category>
		<category><![CDATA[Fibrodysplasia ossificans progressiva]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2924</guid>
		<description><![CDATA[Continuing with our goal to synthesize three compounds as ALK2 inhibitors, let’s refer back to Scheme 2 in the previous post on this topic, compounds 6, 8 and 9 were synthesized in good yields (65-90%), however compound 10 could not be obtained. &#160; Different conditions were tested to induce the cyclization of the bromo-pyrazine-2-carboxamide 9 <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors-continuation-2/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">Continuing with our goal to synthesize three compounds as ALK2 inhibitors, let’s refer back to Scheme 2 in the previous post on this topic, compounds <strong>6</strong>, <strong>8</strong> and <strong>9</strong> were synthesized in good yields (65-90%), however compound <strong>10</strong> could not be obtained.</p>
<div id="attachment_2597" style="width: 748px" class="wp-caption alignnone"><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM.png" alt="" width="738" height="522" class=" wp-image-2597" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM.png 918w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM-300x212.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM-768x544.png 768w" sizes="(max-width: 738px) 100vw, 738px" /><p class="wp-caption-text">Scheme 2. Synthesis route 1</p></div>
<p>&nbsp;</p>
<p style="text-align: justify;">Different conditions were tested to induce the cyclization of the bromo-pyrazine-2-carboxamide <strong>9</strong> to the target bromo-pyrazin-2-amine <strong>10</strong>. This reaction mostly yielded starting material <strong>9 </strong>and by-product <strong>11</strong> in low yields (&lt;15%). After several attempts, this approach (acid/heat) was abandoned.</p>
<p>&nbsp;</p>
<div id="attachment_2926" style="width: 746px" class="wp-caption alignnone"><img src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/06/Screen-Shot-2019-06-13-at-4.17.14-PM.png" alt="" width="736" height="592" class=" wp-image-2926" /><p class="wp-caption-text">Scheme 3. Synthesis route 2</p></div>
<p style="text-align: justify;">An alternative synthetic route is shown in Scheme 3.  Here, aminopirazine <strong>12</strong> will be reduced with diisobutylaluminium hydride (DIBAL-H) to yield carbaldehyde <strong>13</strong>, which then will be reacted with diamine <strong>6</strong> (previously synthesized) at 200 <sup>o</sup>C using dimethylacetamide (DMA) as a solvent. This last step can be carried out in a microwave reactor and should yield the cyclized compound pyridinpyrazin-2-amine <strong>14</strong>, which can be brominated with <em>N</em>-Bromosuccinimide (NBS) to yield compound <strong>10</strong>.</p>
<p style="text-align: justify;">As it was mentioned before, <strong>10 </strong>could not be synthesized by the previously proposed route. The new route is adapted from international patent WO 2008/071937 and we hope in this way we can access to this key intermediate in 150-200 mg scale to move forward with more reactions.</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors-continuation-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Growing co-crystallized fragments to ligands of the transcription factor brachyury (T)</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/growing-co-crystallized-fragments-to-ligands-of-the-transcription-factor-brachyury-t/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/growing-co-crystallized-fragments-to-ligands-of-the-transcription-factor-brachyury-t/#respond</comments>
		<pubDate>Wed, 24 Apr 2019 21:15:14 +0000</pubDate>
		<dc:creator><![CDATA[Louisa Temme]]></dc:creator>
				<category><![CDATA[Chordoma]]></category>
		<category><![CDATA[Louisa Temme]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2758</guid>
		<description><![CDATA[In order to develop ligands addressing different possible binding sites of the transcription factor brachyury, fragments co-crystallized with this protein should be developed into ligands by using the program SparkTM (Cresset®). Brachyury (T, TBXT) is an essential regulator of the notochord development. Brachyury is primarily expressed in the embryo but not in the majority of normal <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/growing-co-crystallized-fragments-to-ligands-of-the-transcription-factor-brachyury-t/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p>In order to develop ligands addressing different possible binding sites of the transcription factor brachyury, fragments co-crystallized with this protein should be developed into ligands by using the program Spark<sup>TM </sup>(Cresset<sup><span style="font-size: 11.25px;">®</span></sup>).</p>
<p>Brachyury (T, TBXT) is an essential regulator of the notochord development. Brachyury is primarily expressed in the embryo but not in the majority of normal adult tissue. It is known that brachyury is overexpressed in chordoma, a primary bone cancer, and plays a role in the disease pathogenesis. Chordoma affects the skull-base, the mobile spine and the sacrum. It is a slow-growing, malign cancer that is locally invasive and has a tendency to recur although a surgical and/or radiation therapy was conducted.<sup>1</sup></p>
<p>It is hypothesized that chordoma is originated from embryonic notochordal remnants. Brachyury is proposed to act as an aberrantly activated transcription factor and thereby be oncogenic. No approved targeted therapies, chemotherapies or immunotherapies are available for chordoma and no small-molecule inhibitors for brachyury have been developed.<sup>1 </sup>Therefore, a fragment-based approach should be explored to develop ligands for brachyury to study this protein.</p>
<p>Our colleagues Joseph Newman and Opher Gileadi at SGC Oxford co-crystallized wild-type human brachyury protein with various fragments which bind to the sites A-E (Figure 1, left). Thankfully, they provided the fragment and protein structures to us so that we can explore the usage of the Spark<sup>TM </sup>growing approach to develop ligands for these binding sites.</p>
<p><img class="wp-image-2759 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture1-300x121.png" alt="" width="592" height="239" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture1-300x121.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture1-768x310.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture1.png 974w" sizes="(max-width: 592px) 100vw, 592px" />Figure 1. Left: Aligned X-ray structures of the human wild-type brachyury protein in complex with fragments at different binding sites (A-E). These first crystallization structures contain Cd<sup>2+</sup>ions (green balls). Right: Binding site A close to loop with D177 and in proximity to residue Y88.<sup>2</sup></p>
<p>First, we focused on binding site A since most fragments bind to this binding site and site A is close to a loop that is mutated in chordoma-linked variant G177D<sup>3 </sup>and to the amino acid residue Y88 that, if mutated, affects binding to effector proteins<sup>4 </sup>(Figure 1, left).</p>
<p><img class="wp-image-2761 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture2-300x86.png" alt="" width="607" height="174" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture2-300x86.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture2-768x220.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture2.png 974w" sizes="(max-width: 607px) 100vw, 607px" /></p>
<p>Figure 2. Fragment <strong>1 </strong>and <strong>2 </strong>co-crystallized in the binding site A of wild-type TBXT.</p>
<p>21 fragments were co-crystallized to binding site A. In Figure 2, the binding modes of two co-crystallized fragments are displayed. Fragments <strong>1 </strong>and <strong>2 </strong>show interactions or close proximity to two of the three amino acids Ser129, Ser89 and Arg180. Therefore, the growing approach of the program Spark<sup>TM </sup>should be used to identify new ligands that are able to form all three interactions. One growing approach started from the amino group of fragment <strong>1 </strong>and was guided by fragment <strong>2 </strong>towards the region of its carboxylate group (Figure 3).</p>
<p><img class="wp-image-2763 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture3-300x171.png" alt="" width="484" height="276" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture3-300x171.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture3-768x438.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture3-780x445.png 780w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture3.png 781w" sizes="(max-width: 484px) 100vw, 484px" /></p>
<p>Figure 3: Spark<sup>TM </sup>growing approach starting from fragment <strong>1 </strong>towards Arg180 guided by fragment <strong>2</strong>. The functional groups of fragments <strong>1 </strong>and <strong>2 </strong>revealing H-bond interactions with amino acid residues are marked with the following colors: Ser129 (red), Ser89 (blue), Arg180 (green).</p>
<p>To achieve new ligands with similar properties in certain areas so-called field points were used. They are ‘condensed representations of electrostatic, hydrophobic and shape properties’ (Cresset<sup><span style="font-size: 11.25px;">®</span></sup>) of those areas where they are placed by the program Spark<sup>TM</sup>. Regarding the growing approach of fragment <strong>1 </strong>and <strong>2 </strong>the hydrophobic field point of the phenyl ring and the negative field point of the carboxylate group of fragment <strong>2 </strong>were used. In total three of the 21 fragments bound to site A were used as starting points and each of them were grown in the area of two different fragments. The results were clustered by Spark<sup>TM </sup>depending on their structural similarity. Those compounds with the highest score of the first 20 clusters ranked according their scores were chosen to analyze their interactions by docking into binding site A using the docking program Flare<sup>TM </sup>(Cresset<sup><span style="font-size: 11.25px;">®</span></sup>). 4,000 docking results were inspected visually and compounds with a high docking score, high electrostatic complementarity and high number of interactions to the binding site were picked.</p>
<p>Figure 4 shows the docking pose of the example compound <strong>3 </strong>that was obtained by docking <strong>3 </strong>in binding site A of brachyury using Flare<sup>TM</sup>. Besides other criteria like docking score and electrostatic complementarity following interactions of <strong>3 </strong>are promising for the co-crystallization of this compound with brachyury: two H-bond interactions of the positively charged amino moiety to Ser129 and His126, the proximity of the amide carbonyl-group to Ser89 and the H-bond interactions of the oxazole O-atom and N-atom towards Arg180.</p>
<p><img class="wp-image-2765 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture4-300x232.png" alt="" width="454" height="351" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture4-300x232.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Picture4.png 633w" sizes="(max-width: 454px) 100vw, 454px" />Figure 4. Binding mode of new compound <strong>3 </strong>obtained by docking into binding site A of wild-type brachyury with Flare<sup>TM</sup>. H-bond interactions are marked with green dotted lines.</p>
<p>Additionally, new compounds were obtained by searching in the Enamine REAL database for similar compounds to those compounds that were found by the Spark<sup>TM </sup>approach and that showed promising docking results in Flare<sup>TM</sup>.</p>
<p>A selection of compounds that are identical or slightly different than those found in the Spark<sup>TM </sup>approach as well as compounds that represent similar ones to the Spark<sup>TM </sup>hits were purchased and will be tested regarding their ability to co-crystallize with brachyury. If the compounds bind to this transcription factor, they will represent promising starting points for future ligands of brachyury.</p>
<p>&nbsp;</p>
<p>(1) Sharifnia, T., <em> Med. (N. Y., NY, U. S.)</em>, <strong>2019</strong>, <em>25</em>, 292-300.</p>
<p>(2) Joseph Newman and Opher Gileadi, SGC Oxford, University of Oxford, UK.</p>
<p>(3) Pillay, N., <em>Nat. Genet.</em>, <strong>2012</strong>, <em>44</em>, 1185-1187.</p>
<p>(4) Beisaw, A., <em>EMBO reports</em>, <strong>2018</strong>, <em>19</em>, 118-134.</p>
<p>&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/growing-co-crystallized-fragments-to-ligands-of-the-transcription-factor-brachyury-t/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novel Hinge Binders: N-Methyl-azaindoles</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/novel-hinge-binders-n-methyl-azaindoles/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/novel-hinge-binders-n-methyl-azaindoles/#respond</comments>
		<pubDate>Tue, 02 Apr 2019 18:30:55 +0000</pubDate>
		<dc:creator><![CDATA[Sean O'Byrne]]></dc:creator>
				<category><![CDATA[Sean O'Byrne]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2644</guid>
		<description><![CDATA[One goal of the CaMKK2 project is to explore the chemistry and biology of novel hinge binders. Various hinge binders showing CaMKK2 inhibition have been identified in the literature and through testing of compounds synthesized in the SGC. Of note in this search was a recent publication by Price et al. (Bioorg. Med. Chem. Lett., <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/novel-hinge-binders-n-methyl-azaindoles/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p>One goal of the CaMKK2 project is to explore the chemistry and biology of novel hinge binders. Various hinge binders showing CaMKK2 inhibition have been identified in the literature and through testing of compounds synthesized in the SGC. Of note in this search was a recent publication by Price <em>et al</em>. (<em>Bioorg. Med. Chem. Lett</em>., <strong>2018</strong>, <em>28</em>, 1958–1963), in which molecules based on 7-azaindole (<strong>1,2</strong>) and 2-amino-pyrimidine (<strong>3</strong>) (<strong>Figure 1</strong>) cores showed excellent activity in an enzymatic CaMKK2 assay.</p>
<div id="attachment_2645" style="width: 790px" class="wp-caption alignnone"><img class="wp-image-2645 size-large" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-1-1024x283.png" alt="" width="780" height="216" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-1-1024x283.png 1024w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-1-300x83.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-1-768x213.png 768w" sizes="(max-width: 780px) 100vw, 780px" /><p class="wp-caption-text"><strong>Figure 1</strong>: Azaindole based CaMKK2 inhibitors</p></div>
<p>Although the compounds have good potency, they are promiscuous, showing poor selectivity in a small screen against 48-86 different kinases. Indeed between 15-30% of the kinases in the panel were inhibited with an IC<sub>50</sub> &lt;100 nM.</p>
<p>Small modifications to the hinge binding region of pharmacophore can have drastic effects on the binding mode, and therefore the selectivity and potency, of inhibitors. It was decided to probe if <em>N</em>-methylation of the azaindole core could be tolerated in CaMKK2. <em>N</em>-methyl azaindole <strong>4 </strong>(<strong>Figure 1</strong>) was synthesized and sent for testing in a CaMKK2 enzyme inhibition assay. The compounds showed moderate activity giving an IC<sub>50 </sub>of 183 nM. The compound also gave had good solubility (125 µM) and was membrane permeable. It was decided to synthesis a small library of compounds based on <strong>4</strong> to see if more potent compounds based on this scaffold.</p>
<p>The compounds were relatively easy to access synthetically. <em>N</em>-methylation of 2-iodo-4-chloro-7-azaindole followed by two Suzuki couplings and an ester hydrolysis allowed quick access to the desired compounds. Conveniently, both Suzuki coupling could be carried using microwave conditions with reactions going to completion in 30 minutes (<strong>Scheme 1</strong>).</p>
<div id="attachment_2647" style="width: 790px" class="wp-caption alignnone"><img class="size-large wp-image-2647" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Scheme-1-1-1024x245.png" alt="" width="780" height="187" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Scheme-1-1-1024x245.png 1024w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Scheme-1-1-300x72.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Scheme-1-1-768x184.png 768w" sizes="(max-width: 780px) 100vw, 780px" /><p class="wp-caption-text"><strong>Scheme 1</strong>: Sequential Suzuki reactions utilizing a microwave reactor to greatly reduce reaction times.</p></div>
<p>In choosing what analogues to make in the library I wanted to probe the effects of electron withdrawing and donating groups, lipophilicity and to determine the effect of extending the molecules with morpholino- groups pointing out of the binding pocket towards the solvent. The library of compounds synthesized is shown in <strong>Figure 2</strong>.</p>
<div id="attachment_2648" style="width: 790px" class="wp-caption alignnone"><img class="size-large wp-image-2648" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-2-1024x515.png" alt="" width="780" height="392" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-2-1024x515.png 1024w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-2-300x151.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/04/Figure-2-768x386.png 768w" sizes="(max-width: 780px) 100vw, 780px" /><p class="wp-caption-text">Figure 2: Library of N-methyl-azaindoles synthesized and sent for a CaMKK2 enzyme inhibition assay.</p></div>
<p>The compounds have been shipped and we are awaiting the results from the enzyme inhibition assay. If any of the compounds have good activity, the best will be sent for a selectivity profiling using KINOMEscan screening platform provided by DiscoverX. From this we will learn if <em>N</em>-methylation can indeed modulate selectivity across the kinome.</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/novel-hinge-binders-n-methyl-azaindoles/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Synthesis of promiscuous ALK2 inhibitors</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors/#respond</comments>
		<pubDate>Tue, 19 Mar 2019 20:34:09 +0000</pubDate>
		<dc:creator><![CDATA[Alfredo Picado]]></dc:creator>
				<category><![CDATA[ACVR1/ALK2]]></category>
		<category><![CDATA[Alfredo Picado]]></category>
		<category><![CDATA[Diffuse intrinsic pontine glioma]]></category>
		<category><![CDATA[Fibrodysplasia ossificans progressiva]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2598</guid>
		<description><![CDATA[In a collaboration between SGC-University of North Carolina-Chapel Hill and M4K Pharma, we plan to synthesize 3 different imidazopyridin pyrazines as promiscuous kinase ALK2 inhibitors, compounds 1-3, Scheme 1. The first step will be the synthesis of key intermediate 10, Scheme 2.  The proposed synthesis begins with a nucleophilic aromatic substitution on compound 4 to <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p>In a collaboration between SGC-University of North Carolina-Chapel Hill and M4K Pharma, we plan to synthesize 3 different imidazopyridin pyrazines as promiscuous kinase ALK2 inhibitors, compounds <strong>1-3</strong>, Scheme 1.</p>
<div id="attachment_2596" style="width: 994px" class="wp-caption alignnone"><img class="size-full wp-image-2596" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.27-PM.png" alt="" width="984" height="346" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.27-PM.png 984w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.27-PM-300x105.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.27-PM-768x270.png 768w" sizes="(max-width: 984px) 100vw, 984px" /><p class="wp-caption-text">Scheme 1. ALK2 inhibitors</p></div>
<p>The first step will be the synthesis of key intermediate <strong>10</strong>, Scheme 2.  The proposed synthesis begins with a nucleophilic aromatic substitution on compound <strong>4</strong> to get nitropyridine <strong>5</strong>, then reduction with hydrogen on palladium/carbon to obtain the pyridine-3,4-diamine <strong>6</strong>.</p>
<p>On the other hand, aminopyrazine <strong>7</strong> will be saponified to the aminopyrazine sodium salt <strong>8</strong>, which will be coupled with  compound <strong>6</strong> using peptide coupling reagent HATU to form bromopyrazine carboxamide <strong>9</strong>, followed by heating in presence of acetic acid to yield the cyclized intermediate 5-bromo-3-(1-ethyl-1<em>H</em>-imidazo[4,5-<em>c</em>]pyridin-2-yl)pyrazin-2-amine <strong>10</strong>.</p>
<div id="attachment_2597" style="width: 928px" class="wp-caption alignnone"><img class="size-full wp-image-2597" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM.png" alt="" width="918" height="650" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM.png 918w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM-300x212.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/03/Screen-Shot-2019-03-19-at-4.22.42-PM-768x544.png 768w" sizes="(max-width: 918px) 100vw, 918px" /><p class="wp-caption-text">Scheme 2. Synthesis route 1</p></div>
<p>If we succeed with the proposed synthesis of imidazopyridine pyrazine <strong>10</strong>, then soon we will present next steps to get to target compounds <strong>1-3</strong></p>
<p>This collaboration is the under supervision of Dr. David Drewry.</p>
<p>Synthesis routes were adapted from international patents WO 2006/063167 A1, WO 2008/071937 and <em>ACS Med. Chem. Lett</em>. 2016, 7, 5, 514-519.</p>
<p>&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/synthesis-of-promiscuous-alk2-inhibitors/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quinoline Series: Synthesis</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/quinazoline-series-synthesis/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/quinazoline-series-synthesis/#respond</comments>
		<pubDate>Sun, 24 Feb 2019 22:58:15 +0000</pubDate>
		<dc:creator><![CDATA[Benjamin Eduful]]></dc:creator>
				<category><![CDATA[Ben Eduful]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2434</guid>
		<description><![CDATA[We have received some very interesting biological data for our CaMKK2 inhibitor series (furopyridine, Azaindole and quinoline) and I will be sharing the data in the coming weeks, but before that, I wanted to share my synthetic efforts towards our quinoline series. Initial synthesis of quinoline analogs: Starting with 6-Bromo-4-chloroquinoline, a two (2) step synthetic <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/quinazoline-series-synthesis/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">We have received some very interesting biological data for our CaMKK2 inhibitor series (furopyridine, Azaindole and quinoline) and I will be sharing the data in the coming weeks, but before that, I wanted to share my synthetic efforts towards our quinoline series.</p>
<p><strong>Initial synthesis of quinoline analogs</strong>:</p>
<p style="text-align: justify;">Starting with 6-Bromo-4-chloroquinoline, a two (2) step synthetic scheme was devised where the bromine (Br) synthetic handle was first substituted (with an appropriate boronic acid/ester), followed by the chlorine (Cl) , <strong>Figure 1</strong>, after testing many different reaction conditions for selectivity.</p>
<p style="text-align: center;"><strong>Figure 1: Synthesis of quinoline series</strong></p>
<p><img class=" wp-image-2526 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-1-300x67.png" alt="" width="416" height="93" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-1-300x67.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-1.png 569w" sizes="(max-width: 416px) 100vw, 416px" /></p>
<p style="text-align: justify;">A number of analogs were prepared using the above synthetic strategy, for example, the synthesis of 2-cyclopentyl-4-(6-(4-(methylsulfonyl)phenyl)quinolin-4-yl)benzoic acid was achieved using the above described method, <strong>Scheme 1</strong>.</p>
<p style="text-align: center;"><strong>Scheme 1: Synthesis of quinoline analog</strong></p>
<p><img class="wp-image-2527 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-2-300x88.png" alt="" width="701" height="206" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-2-300x88.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-2-768x226.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-2.png 936w" sizes="(max-width: 701px) 100vw, 701px" /></p>
<p style="text-align: justify;">Although this synthetic strategy led to the synthesis of some analogs, it was not without challenges. For instance, selectivity for the Br was not always achieved as disubstituted products were common in some cases due to the activated 4-position of the Cl.</p>
<p style="text-align: justify;">In order to overcome these challenges and to allow for rapid synthesis of different analogs over a short period of time, a strategy to first install the cyclopentyl derivative was sort after. In the synthetic scheme below, <strong>Scheme 2</strong>, 6-chloroquinolin-4-ol, <strong>101</strong>, was treated with triflic anhydride in the presence of DIPEA in DCM to obtain 6-chloroquinolin-4-yl trifluoromethanesulfonate, <strong>102</strong>. This compound was able to undergo the Suzuki cross coupling reaction to obtain compound <strong>103</strong>. With this compound (<strong>103</strong>) in hand, a number of different analogs are being generated in our search for active CaMKK2 chemical probes, for example compound <strong>105</strong>, <strong>Scheme 2</strong>.</p>
<p style="text-align: center;"><strong>Scheme 2: Synthesis of quinoline analog via new route</strong></p>
<p><img class=" wp-image-2528 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-3-300x71.png" alt="" width="758" height="179" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-3-300x71.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-3-768x182.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-3-1024x242.png 1024w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-3.png 1282w" sizes="(max-width: 758px) 100vw, 758px" /></p>
<p>We are also looking to exploring the 7-position of the quinoline with similar substitutions to the 6-position (<strong>Figure 2</strong>), quinoline derivative 1. Other anticipated analogs will include O-alkylations (quinoline derivatives 2 and 3), N-alkylations or peptide couplings or Hartwig-Buchwald aminations (quinolines derivatives 4 and 5) etc. Details of such reactions will be communicated in due course.</p>
<p style="text-align: center;"><strong>Figure 2: Exploration of other quinoline analogs</strong></p>
<p><img class=" wp-image-2529 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-4-300x81.png" alt="" width="504" height="136" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-4-300x81.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-4-768x207.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2019/02/Quinoline-4.png 858w" sizes="(max-width: 504px) 100vw, 504px" /></p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/quinazoline-series-synthesis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Selective CDKL2 inhibitors &#8211; molecular modeling</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/selective-cdkl2-inhibitors-molecular-modeling/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/selective-cdkl2-inhibitors-molecular-modeling/#respond</comments>
		<pubDate>Fri, 21 Dec 2018 02:02:27 +0000</pubDate>
		<dc:creator><![CDATA[Louisa Temme]]></dc:creator>
				<category><![CDATA[Louisa Temme]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2325</guid>
		<description><![CDATA[At SGC we are interested in developing protein kinase inhibitors with a high selectivity towards other protein kinases. Based on lead compounds from the literature and our group new and selective CDKL2 inhibitors should be designed, synthesized and tested. Carla Alamillo, a former member of our group, worked on this topic and mentioned in her <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/selective-cdkl2-inhibitors-molecular-modeling/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">At SGC we are interested in developing protein kinase inhibitors with a high selectivity towards other protein kinases. Based on lead compounds from the literature and our group new and selective CDKL2 inhibitors should be designed, synthesized and tested. Carla Alamillo, a former member of our group, worked on this topic and mentioned in her last entry in the open notebook about this topic  (<a href="https://thesgc.github.io/static-openlabnotebooks/sns-032-analogues-update/">https://thesgc.github.io/static-openlabnotebooks/sns-032-analogues-update/</a>) the pro-mising role of SNS-032 as a starting point for new protein kinase inhibitors (Figure 1).<br />
SNS-032 shows a low K<sub>d</sub>value for CDKL2 (48 nM) but also for many other kinases. This means the selectivity of this compound towards other protein kinases is low. In contrast, CAF-181 synthesized by Carla (compound 11 in Carla’s entry) shows low K<sub>d</sub>values for CDKL2 and CDK7 and a high selectivity towards the other kinases tested. Additionally, CAF-181 reveals a moderate CDKL2 IC<sub>50</sub>value of 417 nM. Therefore, CAF-181 represents a good lead compound for the development of new CDKL2 inhibitors with improved selectivity towards CDK7.</p>
<p style="text-align: justify;"><img class="wp-image-2327 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture1-1-300x174.png" alt="" width="694" height="402" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture1-1-300x174.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture1-1.png 668w" sizes="(max-width: 694px) 100vw, 694px" /></p>
<p style="text-align: justify;"><strong>Figure 1. </strong>Lead compounds SNS-032 and CAF-181 and their respective K<sub>d </sub>values.</p>
<p style="text-align: justify;">To design new compounds the molecular modeling software Flare<sup>TM</sup>(Cresset<sup>®</sup>) was used. The first step for the <em>in silico </em>docking is the selection of the crystal structure of the respective protein. Two crystal structures of CDKL2 are available on the PDB website (<a href="https://www.rcsb.org/">https://www.rcsb.org</a>) but not published in a journal yet. One crystal structure is co-crystallized with the compound TCS 2312 (PDB-ID 4BBM) and the other with the compound DKI (PDB-ID 4AAA) (Figure 2). The 2D interaction maps (<a href="https://www.rcsb.org/structure/4AAA">https://www.rcsb.org/structure/4AAA</a> and <a href="https://www.rcsb.org/structure/4BBM">https://www.rcsb.org/structure/4BBM</a>) have to be flipped vertically to match the same amino acid residues. Interestingly, Val83 (Figure 2, blue box) seems to be an impor-tant interaction partner for the ligands since both compounds reveal two H-bond interactions with Val83.</p>
<p style="text-align: justify;"><img class="wp-image-2328 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture2-300x181.png" alt="" width="629" height="380" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture2-300x181.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture2.png 600w" sizes="(max-width: 629px) 100vw, 629px" /></p>
<p style="text-align: justify;"><strong>Figure 2. </strong>Crystal structures of CDKL2: co-crystallized with TCS 2312 (A, PDB-ID 4BBM, DOI: 10.2210/pdb4BBM/pdb) and co-crystallized with DKI (B, PDB-ID 4AAA, DOI: 10.2210/pdb4AAA/pdb). Black dashed lines indicate hydrogen bonds, salt bridges, and metal interactions. Green solid lines show hydrophobic interactions and green dashed lines show π-π and π-cation interactions (<a href="https://www.rcsb.org/structure/4BBM">https://www.rcsb.org/structure/4BBM</a> and <a href="https://www.rcsb.org/structure/4AAA">https://www.rcsb.org/structure/4AAA</a>).</p>
<p style="text-align: justify;">During the <em>in silico </em>docking studies the crystal structure 4BBM was used because the structure 4AAA reveals an unresolved amino acid sequence ending with Ala148 and NME148A (Figure 3B, black box). Unfortunately, this sequence part also contains the amino acid Phe147 that forms a part of the active site and likely interacts with inhibitors. However, the protein structure used for the docking should contain a fully resolved amino acid sequence in this area. The protein structure 4BBM provides a fully resolved amino acid sequence which makes it suitable for <em>in silico </em>docking.</p>
<p style="text-align: justify;"><img class="wp-image-2329 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture3-300x81.png" alt="" width="870" height="235" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture3-300x81.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture3-768x208.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture3.png 974w" sizes="(max-width: 870px) 100vw, 870px" /></p>
<p style="text-align: justify;"><strong>Figure 3. </strong>Structure of CDKL2 co-crystallized with either TCS 2312 (orange, A, PDB-ID 4BBM) or DKI (dark red, B, PDB-ID 4AAA). The dashed green and orange lines indicate H-bond interactions and the purple lines CH-π interactions. Docked ligands are shown as sticks. Oxygen and nitrogen atoms are colored in red and blue, respectively.</p>
<p style="text-align: justify;">However, Phe147 in structure 4BBM is not clarified. Instead of the phenyl ring a methyl group is visible. Capping by the docking program Flare<sup>TM</sup> did not result in phenylalanine but just in a partially aromatic phenyl ring of this amino acid (Figure 3A, black box). This problem was solved by mutation of this position into a phenylalanine.</p>
<p style="text-align: justify;">To investigate the selectivity of newly designed compounds they should also be investigated during the <em>in silico </em>docking into the crystal structure of CDK7 with the PDB-ID 1UA2.</p>
<p style="text-align: justify;">The next step of <em>in silico</em> docking into the CDKL2 structure 4BBM included the validation of the crystal structure and the docking protocol. After preparation and minimization of the crystal structure the co-crystallized ligand TCS 2312 should be redocked into the active site. However, the co-crystallized ligand TCS 2312 shows different bond orders/tautomeric states as well as a different protonation state on the basic nitrogen than the literature compound TCS 2312. To calculate the RMSD value between the binding mode of the structurally corrected and redocked TCS 2312 and the co-crystallized ligand the co-crystallized binding mode had to be corrected because Flare<sup>TM</sup> can only calculate a RMSD value between structurally identical compounds. Therefore, the co-crystallized ligand was corrected and only the resorcinol moiety was minimized to achieve a planar aromatic system. In this way the binding mode of the co-crystallized ligand was changed as little as possible. Then, the corrected, co-crystallized ligand TCS  2312 was minimized and the structure at physiological pH was generated. Afterwards, this compound was docked into the crystal structure 4BBM. Figure 4A shows the similar orientation of corrected, co-crystallized TCS 2312 (yellow) and the redocked ligand (purple). The similar orientation of both binding modes and the hereby resulting low RMSD value<br />
(1.65 Å) suggest that the corrected CDKL2 protein crystal structure 4BBM and the docking protocol are suitable for the <em>in silico </em>docking of new compounds.</p>
<p style="text-align: justify;"><img class="wp-image-2330 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture4-300x181.png" alt="" width="762" height="460" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture4-300x181.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture4-768x463.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture4.png 943w" sizes="(max-width: 762px) 100vw, 762px" /></p>
<p style="text-align: justify;"><strong>Figure 4. </strong>Predicted binding modes of TCS 2312 (A, purple), CAF-181 (B) and SNS-032 (C and D) obtained by docking into the CDKL2 crystal structure with the PDB-ID 4BBM.Binding mode of the corrected, co-crystallized ligand TCS 2312 (A, yellow). The dashed green and orange lines indicate H-bond interactions and the purple lines CH-π interactions. Docked ligands are shown as sticks. Oxygen and nitrogen atoms are colored in red and blue, respectively.</p>
<p>&nbsp;</p>
<p style="text-align: justify;">In the Figures 4B-D the docking results of CAF-181 and SNS-032 are shown. The <em>tert</em>-butyl group of both compounds occupies the inner part of the active site whereas the piperazine ring of CAF-181 and the piperidine of SNS 032 point towards the solvent accessible area. The N-atom of the SNS-032 piperidine ring is part of an H-bond interaction with one of the carboxylic acid moieties of either Glu130 (C) or Asp89 (D). Therefore, it might be promising to introduce amide substituents that can interact with those acidic amino acids.</p>
<p style="text-align: justify;">CAF compounds, synthesized and tested previously in our group, were docked into the CDKL2 crystal structure 4BBM and in the CDK7 crystal structure 1UA2. The respective docking scores and electrostatic complementarity<sup>TM </sup>scores of the resulting docking poses reveal a good correlation to the K<sub>d </sub>values of those compounds regarding CDKL2. However, no clear correlation was found regarding docking of CAF compounds in CDK7. This observation could be explained with the larger active site of CDK7 and its many solvent accessible areas that could facilitate binding of structurally diverse compounds.</p>
<p style="text-align: justify;">Interestingly, <em>in silico</em> docking of SNS-032 and CAF-181 in the active site of CDK7 reveal  curved orientations of both compounds (Figure 5). The green color of the electrostatic complementarity<sup>TM </sup>surface of the SNS-032 binding mode in Figure 5C indicates a high electrostatic complementarity<sup>TM </sup>of the ligand to this active site which could be the reason for the high inhibitory activity of SNS-032 regarding CDK7.</p>
<p style="text-align: justify;"><em><img class="wp-image-2331 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture5-300x180.png" alt="" width="751" height="451" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture5-300x180.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture5-768x461.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/122018_Picture5.png 962w" sizes="(max-width: 751px) 100vw, 751px" /></em></p>
<p style="text-align: justify;"><strong>Figure 5. </strong>Predicted binding modes obtained by docking into the CDK7 crystal structure with the PDB-ID 1UA2:<br />
(A) SNS-032. (B) SNS-032 with the electrostatic potential surface of CDK7. (C) SNS-032 with its electrostatic complementarity<sup>TM </sup>surface. (D) CAF-181. The dashed green and orange lines indicate H-bond interactions and the purple lines CH-π interactions. Docked ligands are shown as sticks. Oxygen and nitrogen atoms are colored in red and blue, respectively.</p>
<p style="text-align: justify;">Based on this observation new CDKL2 inhibitors should reveal restrained flexibility to avoid the curved orientation in CDK7 and thereby increase the selectivity towards CDK7. Among others this could be achieved by replacement of the flexible thio-methylene linker by a more rigid linker. In my next entry I will show the docking results of more rigid compounds obtained by both <em>in silico </em>docking into the crystal structure of CDKL2 and CDK7.</p>
<p style="text-align: justify;">Please feel free to suggest other ideas for CDKL2 inhibitors with increased selectivity towards CDK7. If you have any questions or comments, please let me know.</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/selective-cdkl2-inhibitors-molecular-modeling/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shorter procedure to access Thieno[2,3-d]pyrimidines</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/shorter-procedure-to-access-thieno23-dpyrimidines/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/shorter-procedure-to-access-thieno23-dpyrimidines/#respond</comments>
		<pubDate>Thu, 13 Dec 2018 02:23:38 +0000</pubDate>
		<dc:creator><![CDATA[Alfredo Picado]]></dc:creator>
				<category><![CDATA[Alfredo Picado]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2244</guid>
		<description><![CDATA[Continuing with the line of delivering a chemical probe for DRAK2/STK17B kinase, we decided to revise the procedure to synthesize analogs with a thieno[2,3-d]pyrimidine core, which are intended to be used as negative control in our DRAK2 inhibition study. We shortened the synthesis of these pyrimidines to 2 steps from the starting material 6-bromo-4-chlorothieno[2,3-d]pyrimidine 1 <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/shorter-procedure-to-access-thieno23-dpyrimidines/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p>Continuing with the line of delivering a chemical probe for DRAK2/STK17B kinase, we decided to revise the procedure to synthesize analogs with a thieno[2,3-d]pyrimidine core, which are intended to be used as negative control in our DRAK2 inhibition study.</p>
<p>We shortened the synthesis of these pyrimidines to 2 steps from the starting material 6-bromo-4-chlorothieno[2,3-d]pyrimidine <strong>1</strong> and mercaptoacetic acid <strong>2</strong>, Figure 1.  Here, we eliminated a previous step involving the saponification of an ester moiety to get to the carboxylic acid <strong>3</strong>, which is obtained in quantitative yield and easily purified by rinsing with water.</p>
<p>Using this shorter route, we prepared a few analogs <strong>AP-90, AP-94, AP-262-264</strong>, which were recently screened as DRAK2 inhibitors, showing all of them cell potency &gt;10,000 nM; in other words, they are inactive against DRAK2 and because of their structural similarity with the active compounds in this series, they can be used as negative control for future experiments and probe development.</p>
<div id="attachment_2246" style="width: 974px" class="wp-caption alignnone"><img class="size-full wp-image-2246" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Screen-Shot-2018-12-12-at-9.07.31-PM.png" alt="" width="964" height="964" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Screen-Shot-2018-12-12-at-9.07.31-PM.png 964w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Screen-Shot-2018-12-12-at-9.07.31-PM-150x150.png 150w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Screen-Shot-2018-12-12-at-9.07.31-PM-300x300.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Screen-Shot-2018-12-12-at-9.07.31-PM-768x768.png 768w" sizes="(max-width: 964px) 100vw, 964px" /><p class="wp-caption-text">Figure 1. Synthesis of thieno[2,3-d]pyrimidine derivatives.</p></div>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/shorter-procedure-to-access-thieno23-dpyrimidines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CaMKK2 Inhibitor Series</title>
		<link>https://thesgc.github.io/static-openlabnotebooks/camkk2-inhibitor-series/</link>
		<comments>https://thesgc.github.io/static-openlabnotebooks/camkk2-inhibitor-series/#respond</comments>
		<pubDate>Mon, 03 Dec 2018 02:29:11 +0000</pubDate>
		<dc:creator><![CDATA[Benjamin Eduful]]></dc:creator>
				<category><![CDATA[Ben Eduful]]></category>
		<category><![CDATA[SGC UNC Chapel Hill]]></category>
		<category><![CDATA[Understudied Kinases]]></category>

		<guid isPermaLink="false">https://thesgc.github.io/static-openlabnotebooks/?p=2092</guid>
		<description><![CDATA[The line up of inhibitor series (hinge binders) for CaMKK2 currently being pursued include: furopyridine, azaindole (pyrrolopyridine), quinoline, triazolopyridazine, imidazopyrazine, pyrazolopyrimidine. Figure 1. Figure 1: CaMKK2 hinge binders As part of our structure and activity relationships (SAR), we continue to build diversity on the pyridine ring for the furopyridine series, and new compounds added to <a class="more-link" href="https://thesgc.github.io/static-openlabnotebooks/camkk2-inhibitor-series/">Read More ...</a>]]></description>
				<content:encoded><![CDATA[<p style="text-align: justify;">The line up of inhibitor series (hinge binders) for CaMKK2 currently being pursued include: furopyridine, azaindole (pyrrolopyridine), quinoline, triazolopyridazine, imidazopyrazine, pyrazolopyrimidine. <strong>Figure 1</strong>.</p>
<p><img class=" wp-image-2093 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Screen-Shot-2018-11-06-at-11.14.18-AM-300x64.png" alt="" width="483" height="103" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Screen-Shot-2018-11-06-at-11.14.18-AM-300x64.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Screen-Shot-2018-11-06-at-11.14.18-AM-768x163.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Screen-Shot-2018-11-06-at-11.14.18-AM.png 962w" sizes="(max-width: 483px) 100vw, 483px" /></p>
<p style="text-align: center;"><strong>Figure 1: CaMKK2 hinge binders</strong></p>
<p style="text-align: justify;">As part of our structure and activity relationships (SAR), we continue to build diversity on the pyridine ring for the furopyridine series, and new compounds added to the set are provided below in <strong>Figure 2</strong>.</p>
<p><img class=" wp-image-2207 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Camkk2-new-300x125.png" alt="" width="569" height="237" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Camkk2-new-300x125.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Camkk2-new-768x320.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Camkk2-new-780x326.png 780w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/12/Camkk2-new.png 782w" sizes="(max-width: 569px) 100vw, 569px" /></p>
<p style="text-align: center;"><strong>Figure 2: Additional Furopyridine Analogs</strong></p>
<p><strong>The Azaindoles (Pyrrolopyridines)</strong></p>
<p style="text-align: justify;">Below, I provide the synthetic efforts towards the azaindole (pyrrolopyridines) series, (<em><b>Bioorg</b><b>. Med. Chem. Lett. 28 (2018), 1958-1963</b></em>). The goal is to evaluate what effect changes in the acid functionality with/without the isopropyl substituent would have on the activity of this series (<strong>Figure 3</strong>). It is hoped that any observed trend in activity, solubility, permeability etc will guide the discovery efforts of this inhibitor series for CaMKK2.</p>
<p style="text-align: center;"><img class="wp-image-2097 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-1-300x198.png" alt="" width="189" height="125" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-1-300x198.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-1.png 494w" sizes="(max-width: 189px) 100vw, 189px" /></p>
<p style="text-align: center;"><strong>Figure 3: Azaindole Analog</strong></p>
<p><strong>Synthesis of 2-isopropyl-4-(2-(2-methyl-4-(2-morpholinoethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)benzoic acid, BE2-041:</strong></p>
<p><strong>a</strong>. Synthesis of &#8216;<strong>A</strong>&#8216; portion (<strong>Figure 3</strong>) of the molecule (<strong>Scheme 1</strong>): Compound <strong>1 </strong>was able to undergo the Grignard reaction to install the isopropyl substituent in compound 2, which was then converted to the corresponding boronic ester derivative, <strong>3</strong>.</p>
<p style="text-align: center;"><strong>Scheme 1: Synthesis of </strong></p>
<p><img class=" wp-image-2103 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-2-300x85.png" alt="" width="406" height="115" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-2-300x85.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-2-768x217.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-2.png 813w" sizes="(max-width: 406px) 100vw, 406px" /></p>
<p>b. Synthesis of &#8216;C&#8217; portion (<strong>Figure 3</strong>) of the molecule (<strong>Scheme 2</strong>): Compound <strong>6</strong> was obtained via the Mitsunobu reaction and subsequently converted to the corresponding boronic ester derivative, <strong>7</strong>.</p>
<p><img class=" wp-image-2104 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-3-300x44.png" alt="" width="681" height="100" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-3-300x44.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-3-768x112.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-3-1024x150.png 1024w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-3.png 1086w" sizes="(max-width: 681px) 100vw, 681px" /></p>
<p>c. Putting it all together: Synthesis of <strong>BE2-041</strong> (<strong>Scheme 3</strong>): Compound <strong>11</strong> (<strong>BE2-041</strong>) was obtained via a series of Suzuki reaction methodologies and a final deprotection reaction to achieve the target compound.</p>
<p><img class=" wp-image-2105 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-4-300x52.png" alt="" width="694" height="120" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-4-300x52.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-4-768x133.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-4-1024x177.png 1024w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-4.png 1095w" sizes="(max-width: 694px) 100vw, 694px" /></p>
<p>Completed compounds compounds of the azaindole series are provided in <strong>Figure 4</strong>.</p>
<p><img class="alignnone wp-image-2100 aligncenter" src="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-Pdts-300x132.png" alt="" width="538" height="237" srcset="https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-Pdts-300x132.png 300w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-Pdts-768x337.png 768w, https://thesgc.github.io/static-openlabnotebooks/wp-content/uploads/2018/11/Pyrrolo-Pdts.png 924w" sizes="(max-width: 538px) 100vw, 538px" /></p>
<p style="text-align: center;"><strong>Figure 4: Completed Azaindole Series </strong></p>
<p>&nbsp;</p>
]]></content:encoded>
			<wfw:commentRss>https://thesgc.github.io/static-openlabnotebooks/camkk2-inhibitor-series/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
